Description
SB 243213 is an orally active, selective and high-affinity 5-HT 2C receptor antagonist with a pK i of 9.37 and a pK b of 9.8 for human 5-HT 2C receptor. SB 243213 shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 has improved anxiolytic profile and has the potential for schizophrenia and motor disordersIn VitroSB 243213 shows little affinity (pK i <6) for cloned human 5-HT 1A, 5-HT 1B, 5-HT 1E, 5- HT 1F and 5-HT 7 receptors. It shows weak affinity (pK i <6.5) for the cloned human 5-HT 1D and D3 receptors and moderate affinity (pK i =6.7) for the cloned human D2 receptor. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoSB 243213 (0.1-10 mg/kg, p.o. 1 h pre-test) dose-dependently and significantly increases the amount of time rats spent in social interaction over 15 min under brightly lit conditions and in an unfamiliar test box. SB 243213 (0.3 mg/kg; p.o.; 1 h pre-test) significantly increases time spent in social interaction. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley experimentally naive rats (220-300 g) Dosage: 0.1, 0.3, 1, 3, 10 mg/kg Administration: PO; 1 hour pre-test Result: Dose-dependently and significantly increased the amount of time rats spent in social interaction over 15 min under brightly lit conditions and in an unfamiliar test box.Form:SolidIC50& Target:Human 5-HT 2C Receptor 9.37 (pKi) human 5-HT 1A Receptor <5.3 (pKi) human 5-HT 1B Receptor 5.5 (pKi) human 5-HT 1D Receptor 6.32 (pKi) human 5-HT 1E Receptor <5.4 (pKi) human 5-HT 1F Receptor 5.35 (pKi) Human 5-HT 2A Receptor 7.01 (pKi) human 5-HT 2B Receptor 7.2 (pKi) Human 5-HT 6 Receptor 6.5 (pKi) Human 5-HT 7 Receptor 5.64 (pKi)